Torrent Pharma Q4 FY26 Revenue Surges 42 Percent as India and Exports Accelerate

Torrent Pharmaceuticals closed Q4 FY26 with a sharp step up in revenue momentum. Total revenue rose to Rs 4,197 crore, up 42 percent year on year from Rs 2,959 crore in Q4 FY25. The quarter stood out because growth was broad based. India led the charge, but the international markets also moved higher together, which is not always the case for a diversified pharma company.

For the full year, the picture was steady rather than explosive. FY26 revenue came in at Rs 13,980 crore, up 21 percent from Rs 11,516 crore in FY25. That mix of a strong fourth quarter and a solid full year suggests the company ended the year with improving run rate. It also highlights that recent execution delivered across both the domestic base and export platforms.

The results presentation is focused on revenue, so investors do not get a direct read here on EBITDA, margins, or profit. But the revenue pattern still matters. It shows where the growth is coming from, how diversified it is, and what parts of the business are doing the heavy lifting.

A quarter defined by India strength and a broad export lift

India remained the anchor and the standout. Q4 FY26 India revenue rose to Rs 2,215 crore versus Rs 1,545 crore in Q4 FY25, a 43 percent increase. Given India already forms the largest piece of the business, that kind of growth is meaningful. It drives scale benefits and can change the mix quickly, especially in a quarter where other regions also grew.

The United States also delivered a strong quarter. Revenue increased 31 percent year on year to Rs 396 crore from Rs 302 crore. For a market that can be volatile for generic drug players, a clean double digit growth print is supportive. It indicates either stronger base business, improved portfolio performance, or a combination of both, though the presentation does not provide product level drivers.

Europe, represented here by Germany, continued to grow at a more measured pace. Germany revenue was Rs 333 crore, up 16 percent from Rs 286 crore a year ago. Brazil showed a stronger rebound, with revenue rising 30 percent to Rs 455 crore from Rs 351 crore.

The biggest percentage jump came from the Others segment. Revenue there climbed to Rs 798 crore from Rs 475 crore, up 68 percent. The disclosure does not break down which geographies sit inside this bucket. Even so, the magnitude suggests either meaningful scale up in a few markets or a favorable base effect. For investors, the key is that the growth is not concentrated only in India. It is also spreading into the long tail of international markets.

Full-year performance shows balanced growth across regions

On the annual view, Torrent Pharma delivered consistent growth across every disclosed geography. India revenue in FY26 was Rs 7,645 crore, up 20 percent from Rs 6,393 crore in FY25. The US and Brazil were both up 24 percent, reaching Rs 1,363 crore and Rs 1,362 crore respectively. Germany grew 10 percent to Rs 1,249 crore.

The Others segment rose 32 percent to Rs 2,361 crore from Rs 1,784 crore. That is a strong full-year number and it adds diversification to the revenue base.

This full-year pattern matters for two reasons. First, it suggests Torrent is not relying on a single geography to deliver growth. Second, it points to resilience. If one market softens in a given quarter, the company has multiple levers to absorb volatility.

Financial summary

What the mix says about execution and risk

The quarter’s 42 percent revenue growth is striking, but the composition is more important than the headline. India’s 43 percent rise indicates a strong domestic operating cycle, whether driven by market share gains, therapy outperformance, or improved distribution. Since India is the largest segment, it can set the tone for the whole company’s reported growth.

At the same time, the export markets did not lag. The US and Brazil both posted 30 percent plus growth in the quarter, while Germany also grew at a healthy mid teens rate. The Others segment added an outsized push.

This matters because pharma growth can be uneven across markets. The US often swings with pricing and competitive intensity. Brazil can be impacted by tenders, currency movements, and policy shifts. Germany tends to be more stable but can be slower. A quarter where every region is positive, and most are strong, typically reflects solid execution and a portfolio that is working.

Looking at the full year helps separate a one-off spike from a sustained trend. FY26 total revenue growth of 21 percent is strong, and it is supported by double digit growth in every region. Even Germany, the slowest growing geography in the disclosure, still grew 10 percent year on year.

The implication is that Torrent is building a more even growth profile. That can reduce dependence on any one geography. It can also allow the company to prioritize capital and management attention where returns are best, without risking an immediate slowdown in the overall base.

Segment comparison (share of revenue)

The shares underline two points. First, India remains just over half of revenue, so domestic performance still carries the most weight. Second, the Others segment is gaining share, especially in the quarter. That increases diversification, though it also raises a question that investors may want answered later, which is what is driving this bucket and how sustainable it is.

Germany’s share is lower versus last year, despite growing in absolute terms. That is because India and Others grew faster. The US share is roughly stable, while Brazil is close to flat on the annual share view.

Closing view for investors: strong finish, broader base

Torrent Pharma’s FY26 story, based on this presentation, is about a stronger finish to the year and a widening set of growth engines. Q4 FY26 revenue growth of 42 percent is not narrow or concentrated. It is led by India, supported by the US and Brazil, and amplified by a strong contribution from the Others segment.

For the full year, the 21 percent revenue growth indicates that the company did not rely only on a single quarter to deliver. Growth across India, the US, Germany, Brazil, and Others suggests a diversified platform that can handle market level volatility better than a one market dependent model.

The missing piece in this document is profitability. Revenue growth is only one part of the investment case, and investors will still want clarity on margins, product mix, and cash generation. But the revenue map itself is encouraging. It points to disciplined execution across geographies and an improving run rate going into the next year.

The quarter’s theme is sustained growth with broad participation. If Torrent can maintain this balance across markets while protecting margins, the revenue trajectory shown in FY26 gives it a solid base to build on.